Novocellbio

Novocellbio is a South Korean private biotechnology company focused on NK cell-based immune cell therapies for cancer, autoimmune disease, and infectious disease applications. The company appears to center its R&D around proprietary NK cell culture and expansion capabilities and has publicly highlighted NOVO-NK as its lead autologous NK cell therapy program. Publicly available materials indicate preclinical antiviral and antitumor work, including studies related to SARS-CoV-2 and lung cancer, and secondary sources suggest at least one program has reached Phase 1/2 development. In addition to therapeutics, some company profiles describe Novocellbio as offering research and development services in autoimmune cell therapy. Overall, the company looks like an early-stage platform-oriented cell therapy biotech rather than a diversified commercial pharma business.